Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma : Episode 10

News

Video

December 12, 2023

Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

Author(s):

Expert insight into how to discuss and manage treatment-related toxicities with cancer patients and their families, emphasizing the importance of early communication and vigilance.

EP: 1.Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

EP: 2.Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

EP: 3.Imaging and Staging Considerations in Renal Cell Carcinoma

EP: 4.Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

EP: 5.Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

EP: 6.Comparing Treatment Combinations in Renal Cell Carcinoma

EP: 7.Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

EP: 8.Sequencing and Second-Line Therapy in RCC: Patient Scenario

EP: 9.Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

Now Viewing

EP: 10.Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

EP: 11.Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

EP: 12.Triple Combination Therapies in RCC: Clinical Trial Insights

EP: 13.Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

Related Content

December 18th 2024

Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

ASH Meeting | Image credit: © Nittaya – stock.adobe.com

December 9th 2024

Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma

November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

December 3rd 2024

NDI-101150 Demonstrates Antitumor Activity, Safety in Heavily Pretreated RCC

December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024